Biotech and emerging health care technology companies both fit into a high-stake poker match on Wall Street. Investors can earn exponential rewards if they are right, or they can lose it all if they make the wrong picks. In many cases, none of these stocks have any true market correlation on their own due to such wide swings. Unfortunately two of these high-stakes companies are hitting the skids on Friday.
pSivida Corp. (NASDAQ: PSDV) is getting crushed after the U.S. Food and Drug Administration (FDA) decided not to approve its treatment for an eye disease that is common in diabetic patients. Its stock is down 44% at $2.12, against a 52-week range of $1.17 to $5.60, and its pre-implosion market cap was only $101 million.
Alimera Sciences Inc. (NASDAQ: ALIM) is following pSivida down the drain, as that FDA denial applied to the treatment licensed and sold by Alimera in other markets. Alimera shares are down 35% at $1.75 in premarket trading, against a 52-week range of $1.26 to $5.69, and its pre-drop market cap was a mere $85 million.
Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) is tanking on news that it will discontinue its phase II trial of Iclusig. This was placed on clinical hold last week by the FDA after some patients suffered arterial thrombosis or other negative side effects. Ariad’s drop is a re-implosion because it already was hammered. Now shares are down 31% at $3.07, against a prior 52-week range of $3.98 to $24.85, and its new market cap is going to be approaching $600 million. Ariad was a $17 stock before last week’s implosion.
Again, the biotech and emerging health care tech sector is one of high-risks and high-rewards. Caveat Emptor!
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.